Indacaterol maleate and glycopyrronium bromide

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, Orion Corporation, Orion Pharma

Conditions

COPDHealthy Volunteers

Phase 1

Absorption of Indacaterol and Glycopyrronium From Ultibro Breezhaler

CompletedNCT04856098

Orion Corporation, Orion PharmaHealthy Volunteers

Start: 2021-05-07End: 2021-09-21Updated: 2021-09-28

Phase 4

Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen

CompletedNCT01985334

Novartis PharmaceuticalsCOPD

Start: 2014-02-14End: 2016-04-29Updated: 2019-03-19

Related Papers

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.

2018-04-1613 citations

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial

Respiratory Research2017-07-1854 citations